Agios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs

Go back to Agios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs

Agios Pharma (AGIO) Misses Q3 EPS by 11c

November 3, 2016 8:40 AM EDT

Agios Pharma (NASDAQ: AGIO) reported Q3 EPS of ($1.63), $0.11 worse than the analyst estimate of ($1.52). Revenue for the quarter came in at $9 million versus the consensus estimate of $7.82 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

... More